Skip to main content
European Cardiology Review logoLink to European Cardiology Review
. 2026 Nov 2;21:e59. doi: 10.15420/ecr.2025.94

Metabolic Modulation in Hypertrophic Cardiomyopathy: A Systematic Review of Clinical and Observational Evidence

Shun Wen Chew 1,✉, Jasmine Cheong Zhen Yi 2, Samuel Lim Jian Rong 2, Nicholas Yip Zhe Wei 2, Mohd Shawal Faizal Mohamad 3, Chim C Lang 3,4, Anna-Maria Choy 3,4
PMCID: PMC13756549  PMID: 43022434

Abstract

Background:

Hypertrophic cardiomyopathy (HCM) is characterised by left ventricular hypertrophy, microvascular dysfunction and chronic energetic inefficiency. Current therapies relieve symptoms or left ventricular outflow tract obstruction but do not directly target these metabolic abnormalities.

Methods:

We systematically searched PubMed, Embase, Google Scholar and ClinicalTrials.gov from 1 January 2000 to 31 May 2025 for randomised trials, observational cohorts, registries and case series (≥3 patients) evaluating fatty acid oxidation inhibitors (perhexiline, trimetazidine), late sodium current inhibition (ranolazine) or sodium–glucose cotransporter 2 inhibitors (SGLT2I) in adults with HCM. Outcomes included exercise capacity, diastolic indices, symptoms, arrhythmia burden and safety.

Results:

Seven HCM-specific studies met inclusion criteria: trimetazidine (one randomised controlled trial [RCT]), perhexiline (one RCT), ranolazine (one RCT, one real-world cohort and one case series) and SGLT2I (one prospective controlled cohort, one nationwide registry). Most enrolled predominantly non-obstructive or mixed HCM. Trimetazidine had neutral effects on peak VO₂, diastolic function and biomarkers. Perhexiline improved phosphocreatine-to-adenosine triphosphate ratios, diastolic indices, peak VO₂ and New York Heart Association class. Ranolazine consistently reduced angina and ventricular ectopy but did not increase peak VO₂. In the included HCM studies, empagliflozin/dapagliflozin exposure in a small prospective cohort was associated with improved E/e′ and New York Heart Association class, while broader SGLT2I use in a diabetic HCM registry was associated with lower mortality and hospitalisation for heart failure.

Conclusion:

Metabolic modulators and SGLT2I could improve diastolic parameters, symptoms and arrhythmia burden in selected, mainly non-obstructive HCM populations but have not demonstrated consistent gains in exercise capacity. Larger, phenotype-stratified randomised trials are needed to define their role alongside contemporary HCM therapies.

Keywords: Hypertrophic cardiomyopathy, metabolic modulation, perhexiline, ranolazine, trimetazidine, sodium–glucose cotransporter 2 inhibitor, diastolic dysfunction


Hypertrophic cardiomyopathy (HCM) is a primary myocardial disorder defined by unexplained left ventricular hypertrophy and characterised by myocyte disarray, interstitial fibrosis, microvascular dysfunction and heightened arrhythmic risk.1,2 Recent epidemiological and genetic data suggest a prevalence approaching 1 in 200 adults, with most familial cases arising from pathogenic variants in sarcomeric proteins, particularly MYH7 and MYBPC3.2–4 Clinical expression is heterogeneous, ranging from asymptomatic individuals to patients with exertional dyspnoea, chest pain, presyncope, AF or advanced heart failure.1,2 Haemodynamically, HCM is broadly categorised into non-obstructive disease and obstructive HCM (HOCM), the latter defined by dynamic left ventricular outflow tract (LVOT) gradients ≥30 mmHg at rest or with provocation.1

The 2024 American Heart Association/American College of Cardiology (AHA/ACC) guideline emphasises that symptoms in HCM arise from several interrelated pathophysiological domains: impaired diastolic filling, increased myocardial oxygen demand, microvascular ischaemia, fibrosis-mediated stiffening, arrhythmogenic substrate and, in obstructive disease, dynamic LVOT obstruction with systolic anterior motion of the mitral valve.1 Notably, microvascular dysfunction and heart failure with preserved ejection fraction (HFpEF)-like elevation in filling pressures contribute substantially to symptoms even in the absence of obstruction.2,5,6 Cardiac MRI studies consistently demonstrate perfusion defects, reduced coronary flow reserve and subendocardial ischaemia that correlate with fibrosis burden and adverse events.5–7

Historical Evolution of Medical Therapy in Hypertrophic Cardiomyopathy

Modern pharmacotherapy in HCM began with the observations of Cohen and Braunwald in 1967, who showed that propranolol improved angina, exercise tolerance and LVOT gradients in patients with “idiopathic hypertrophic subaortic stenosis”.8 This landmark study established β-blockade as the cornerstone of symptom management by reducing heart rate, myocardial oxygen demand and dynamic outflow gradients. Over subsequent decades, calcium channel blockers and disopyramide were incorporated to further modulate LVOT gradients and diastolic filling pressures, while ICDs and sudden death risk stratification transformed long-term management.1,5

More recently, selective myosin inhibition (mavacamten and aficamten) has ushered in a new era by directly targeting hypercontractility and systolic LVOT obstruction.9,10 However, despite these advances, current guideline therapies remain fundamentally haemodynamic and anti-arrhythmic. They do not address the deep metabolic disturbances now recognised as central to HCM pathophysiology.

Energetic and Ionic Abnormalities in Hypertrophic Cardiomyopathy

A large body of mechanistic evidence demonstrates that HCM is fundamentally a disorder of energetic inefficiency and abnormal calcium handling.3,5,11 Phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) reveals reduced myocardial phosphocreatine-to-adenosine triphosphate (PCr/ATP) ratios in overt HCM and in genotype-positive/ phenotype-negative individuals, indicating early high-energy phosphate depletion.3,7,12 Sarcomeric mutations increase ATP cost per unit of tension by destabilising the super-relaxed myosin state, thereby driving chronic energetic strain.11,12 Concurrently, microvascular rarefaction, intramural arteriolar thickening and impaired coronary flow reserve produce patchy subendocardial ischaemia, which correlates with late gadolinium enhancement, arrhythmic risk and progression to heart failure.5,6

At the cellular level, enhanced late sodium current (InaL) impairs Na+/Ca²+ exchange, generating diastolic Ca²+ overload, prolonged relaxation and increased ventricular ectopy.5,13 Collectively, these metabolic, energetic and ionic abnormalities produce diastolic dysfunction and impaired myocardial reserve even in patients with structurally mild disease or without LVOT obstruction.

Rationale for Metabolic and SGLT2-targeted Therapies

The recognition that HCM is an energetic disease provides a compelling mechanistic rationale for therapeutic strategies targeting substrate usage, mitochondrial efficiency and ionic homeostasis.3,5,11 Fatty acid oxidation (FAO) inhibitors such as perhexiline and trimetazidine promote a shift toward glucose oxidation, improving ATP yield per unit of oxygen consumed.3,5,14,15 Ranolazine, through selective inhibition of InaL, reduces intracellular sodium and secondary Ca²+ overload, with the potential to alleviate microvascular ischaemia and ventricular ectopy.13,14,16

Sodium–glucose cotransporter 2 inhibitors (SGLT2I) may also be relevant to HCM through haemodynamic and metabolic effects that overlap with the HFpEF-like physiology observed in some non-obstructive HCM phenotypes, although HCM-specific evidence remains limited.2,5,6,17–19

Need for an Integrated Synthesis

Despite compelling biological rationale, clinical evidence supporting metabolic modulation in HCM is limited, fragmented and heterogeneous. Studies differ widely in phenotype selection, endpoints, follow-up duration and mechanistic characterisation. Importantly, no clinical trial has specifically evaluated these therapies in obstructive HCM, where preload- and afterload-modifying agents may have unpredictable haemodynamic effects. Existing reviews have considered FAO inhibitors, InaL inhibition and SGLT2I in isolation, without an integrated, mechanism-aligned appraisal across drug classes.5

Aim

The objective of this systematic review is to evaluate the clinical and observational evidence regarding perhexiline, trimetazidine, ranolazine and SGLT2I in adult HCM. We aim to characterise their effects on exercise capacity, diastolic function, symptoms, arrhythmia burden and biomarkers, and integrate these findings within contemporary mechanistic understanding and phenotype-specific considerations, as outlined by the 2024 AHA/ACC HCM guideline.1,5

Methods

This systematic review adhered to PRISMA 2020 guidelines and was prospectively registered on PROSPERO (CRD420251230047).20 The review protocol, including search strategy, eligibility criteria, data extraction plan and predefined outcomes, is available online. The final methods reflect the PROSPERO protocol without deviation.

Search Strategy

A comprehensive search was performed across PubMed (MEDLINE), Embase (Ovid), Google Scholar (first 100 results by relevance) and ClinicalTrials.gov from 1 January 2000 to 31 May 2025, according to the predefined PROSPERO protocol.

Search terms combined HCM terminology with metabolic modulator and SGLT2I terms, including: “hypertrophic cardiomyopathy”, “obstructive hypertrophic cardiomyopathy”, “HCM”, “HOCM”; “perhexiline”, “trimetazidine”, “ranolazine”; “empagliflozin”, “dapagliflozin”, “canagliflozin”, “SGLT2 inhibitor”; and “metabolic modulation”, “fatty-acid oxidation”, “cardiac energetics”, “late sodium current”.

Reference lists of included studies and related reviews were hand-searched for additional eligible studies. No language limits were applied during screening, although only English-language full texts were identified. The initial search identified 181 records, consistent with the protocol summary.

Eligibility Criteria

Eligibility was defined prospectively according to the PROSPERO protocol and structured using the PICOS framework:

Population

Adults (≥18 years) with HCM defined by contemporary guideline criteria were eligible, and both obstructive and non-obstructive phenotypes were eligible. Phenocopies (e.g. Fabry disease, amyloidosis), paediatric populations and mixed cardiomyopathy cohorts without extractable HCM-specific data were excluded.

Interventions

Metabolic or energetics-targeting agents:

  • FAO inhibitors – perhexiline, trimetazidine;

  • InaL inhibition – ranolazine; and

  • SGLT2I – including empagliflozin, dapagliflozin and canagliflozin, with additional agent-specific exposures retained as reported in eligible studies.

Comparators

Placebo, standard care or pre–post comparison in single-arm studies.

Outcomes

Clinical, functional, imaging and biomarker endpoints:

  • exercise capacity: peak VO₂, 6-minute walk distance;

  • diastolic function: E/e′, normalised time to peak filling (nTTPF), left ventricular (LV) filling indices;

  • symptoms and functional class: New York Heart Association (NYHA) class, angina class;

  • arrhythmia burden: premature ventricular complexes (PVCs), AF;

  • biomarkers: N-terminal pro B-type natriuretic peptide, troponin; and

  • safety: discontinuation, adverse events.

Mechanistic-only studies without clinical endpoints were excluded.

Study Design

Randomised controlled trials (RCTs), quasi-experimental trials, prospective or retrospective cohorts, registries and case series with ≥3 patients were eligible, while case reports (<3 patients), narrative reviews, editorials and animal or in vitro studies were excluded. These criteria match the structured eligibility table in the protocol.

Study Selection

Two reviewers independently screened all titles and abstracts using a web-based screening platform, followed by full-text review according to the predefined criteria. Disagreements were resolved by consensus.

A PRISMA 2020 flow diagram summarises identification, screening, eligibility and inclusion counts (Figure 1). In total, 181 records were identified. After removal of 45 duplicates, 136 records remained for screening (99 screened in Rayyan and 37 identified from additional sources). After title/abstract screening and full-text assessment, seven studies met the inclusion criteria.

Figure 1: PRISMA 2020 Flow Diagram of Study Identification, Screening, Eligibility and Inclusion.

Figure 1:

Data Extraction

Data were extracted independently in duplicate using a standardised, protocol-driven form. Extracted fields included:

  • study design and setting;

  • sample size and demographic characteristics;

  • HCM phenotype (obstructive versus non-obstructive; LVOT gradient definitions);

  • intervention details (dose, titration, duration);

  • comparator;

  • primary and secondary outcomes;

  • mechanistic endpoints (PCr/ATP, perfusion, nTTPF) where applicable;

  • follow-up duration;

  • safety and adverse events; and

  • study limitations.

When there were multiple publications from the same cohort, the most complete data set was used to prevent duplication.

Risk of Bias Assessment

Risk of bias was independently assessed by two reviewers according to study design, as prespecified in the protocol:

  • randomised controlled trials: Cochrane Risk of Bias 2 (RoB-2) tool;21

  • observational studies and registries: Risk Of Bias In Non-randomised Studies - of Interventions (ROBINS-I);22 and

  • case series: National Institutes of Health Quality Assessment Tool.23

Discrepancies were resolved via consensus discussion.

A summary of the risk of bias assessment is shown in Table 1.

Table 1: Risk-of-bias Assessment of the Included Studies.

Study Agent/Class Design RoB Tool Overall Risk/Quality
Coats et al. 201915 Trimetazidine RCT RoB-2 Low
Abozguia et al. 20104 Perhexiline RCT RoB-2 Some concerns
Olivotto et al. 2018 (RESTYLE-HCM)14 Ranolazine RCT RoB-2 Some concerns
Argirò et al. 202316 Ranolazine Single-arm cohort ROBINS-I Serious
Subramanian et al. 202317 Sodium–glucose cotransporter 2 inhibitor Controlled cohort ROBINS-I Serious
Jung et al. 202518 Sodium–glucose cotransporter 2 inhibitor Nationwide registry ROBINS-I Moderate
Gentry et al. 2016 (RHYME)24 Ranolazine Case series National Institutes of Health case series tool Fair

RCT = randomised controlled trial; RoB-2 = Cochrane Risk of Bias 2 Tool for Randomised Trials; ROBINS-I = Risk Of Bias In Non-randomised Studies - of Interventions.

Data Synthesis

The PROSPERO protocol prespecified a narrative synthesis, with the expectation that quantitative pooling would be unlikely due to:

  • heterogeneity in HCM phenotype (non-obstructive versus mixed);

  • variable interventions and dosing strategies;

  • inconsistent cardiopulmonary exercise testing protocols;

  • multiple definitions of diastolic indices (E/e′, nTTPF, left atrial parameters); and

  • mixed follow-up durations (4 months to >4 years).

Accordingly:

  • No meta-analysis or pooled effect estimates were attempted.

  • Results were synthesised by therapeutic class (FAO inhibitors, InaL inhibition, SGLT2 inhibition).

  • Phenotype-specific findings (obstructive versus non-obstructive) were highlighted where extractable.

Where possible, results were organised across three predefined domains from the protocol:

  1. clinical outcomes (mortality, hospitalisation for heart failure [HHF], symptoms);

  2. functional/imaging outcomes (peak VO₂, E/e′, LVOT gradient, perfusion); and

  3. safety and tolerability.

Patient and Public Involvement

Consistent with the protocol, patients and members of the public were not involved in the design, conduct, analysis or dissemination of this review.

Results

Overview of Included Studies

The search identified 181 records, of which seven HCM-specific clinical studies fulfilled the inclusion criteria after screening and full-text assessment.4,14–18,24 These comprised three randomised controlled trials, two observational cohort studies, one nationwide registry analysis and one case series.

Most included studies enrolled adults with symptomatic non-obstructive or mixed HCM phenotypes; none was designed exclusively for obstructive HCM. Follow-up ranged from 8 weeks to 3 years, and sample sizes varied from 11 participants in the RHYME ranolazine case series to a large national SGLT2I registry cohort.18,24

Because of heterogeneity in study design, phenotype, intervention dose and outcome definitions, quantitative pooling was not feasible. Results are therefore presented qualitatively by drug class.

The characteristics of the included studies, including design, sample size, population and key endpoints are summarised in Table 2.

Table 2: Characteristics of the Included Studies.

Agent/Class Study Design Population n Follow-up Main Endpoints
Trimetazidine Coats et al. 201915 RCT Symptomatic non-obstructive HCM 51 12 weeks Peak VO2 6-minute walk distance, E/e′, NT-proBNP, quality of life
Perhexiline Abozguia et al. 20104 Mechanistic RCT Symptomatic non-obstructive HCM 46 Mean 4.6 months Phosphocreatine-to-adenosine triphosphate ratio, normalised time to peak filling, peak VO₂, New York Heart Association class
Ranolazine Olivotto et al. 2018 (RESTYLE-HCM)14 RCT Symptomatic non-obstructive HCM 80 5 months Peak VO₂, E/e′, NT-proBNP, premature ventricular complex burden
Ranolazine Argirò et al. 202316 Retrospective cohort Mixed HCM 119 Median 2 years Angina, Canadian Cardiovascular Society class, arrhythmias, safety
Ranolazine Gentry et al. 2016 (RHYME)24 Case series Symptomatic HCM 11 8 weeks Angina, dyspnoea, quality of life
Sodium–glucose cotransporter 2 inhibitors Subramanian et al. 202317 Prospective controlled cohort Type 2 diabetes+ non-obstructive HCM 48 6 months E/e′, New York Heart Association class, 6-minute walk distance, NT-proBNP
Sodium–glucose cotransporter 2 inhibitors Jung et al. 202518 Nationwide registry HCM + type 2 diabetes 4,126 Median 3 years Mortality, hospitalisation for heart failure, sudden cardiac death, stroke

HCM = hypertrophic cardiomyopathy; NT-proBNP = N-terminal pro b-type natriuretic peptide; RCT = randomised controlled trial.

Risk of Bias

Risk-of-bias assessments are summarised in Table 1.

Among the three randomised trials, the trimetazidine study was judged to be at low risk of bias across all RoB-2 domains, whereas the perhexiline and RESTYLE-HCM ranolazine trials had some concerns, mainly due to incomplete reporting of randomisation and allocation procedures; other domains were at low risk of bias.

The three non-randomised cohort or registry studies were at moderate to serious risk of bias using ROBINS-I. The nationwide SGLT2I registry was rated as moderate risk, whereas the single-centre SGLT2 cohort and ranolazine real-world cohort were judged to have serious risk of bias, primarily driven by confounding, selection of participants and unblinded outcome assessment.

The RHYME ranolazine case series was rated as fair quality with the National Institutes of Health tool, reflecting clear selection and outcome definitions but small sample size, lack of blinding and short follow-up.

Trimetazidine

A single RCT evaluated trimetazidine in symptomatic non-obstructive HCM.15 Participants were randomised to trimetazidine or placebo in addition to guideline-directed therapy for several months, with peak VO₂ as the primary endpoint. Trimetazidine did not improve exercise capacity; peak VO₂ numerically declined in the active arm compared with placebo, and there was no significant change in 6-minute walk distance. Diastolic parameters, including E/e′, as well as natriuretic peptide concentrations and health-related quality of life scores, were unchanged. No consistent signal for symptom benefit emerged.

Overall, this trial suggests that partial inhibition of FAO with trimetazidine does not confer clinically meaningful improvements in functional capacity, diastolic function or biomarkers in non-obstructive HCM.

Perhexiline

Perhexiline was assessed in a single mechanistically focused, placebo-controlled RCT with an accompanying protocol publication.4 Patients with symptomatic non-obstructive HCM were randomised to perhexiline or placebo, with drug doses titrated to achieve therapeutic plasma levels.

Perhexiline produced clear mechanistic and clinical benefits. Myocardial PCr/ATP ratio increased on ³¹P-MRS, indicating improved energetic status, and exercise-induced impairment in nTTPF was corrected. These changes were paralleled by improvements in exercise capacity: peak VO₂ rose by approximately 2 ml/kg/min versus placebo, and most treated patients improved by at least one NYHA functional class. Natriuretic peptide levels tended to fall in line with better diastolic function.

Adverse events were generally mild and manageable with therapeutic drug monitoring; no severe hepatotoxicity or neuropathy was reported over the relatively short follow-up.

Taken together, perhexiline provides proof-of-concept that more potent FAO inhibition can reverse energetic and diastolic abnormalities and translate into functional gains in non-obstructive HCM, in contrast to the neutral trimetazidine findings.

Ranolazine

Ranolazine was evaluated in one RCT, one real-world HCM cohort study and one small HCM case series.14,16,24 These studies enrolled predominantly non-obstructive or mixed HCM phenotypes. Additional non-HCM refractory angina registry data suggest sustained anti-anginal benefit and acceptable long-term tolerability with ranolazine, but these data were not included in the HCM-specific evidence synthesis.25

The RESTYLE-HCM RCT randomised symptomatic HCM patients to ranolazine or placebo.14 Ranolazine did not increase peak VO₂ or significantly change echocardiographic indices of diastolic function, including E/e′. However, it reduced ventricular ectopy: PVC burden on ambulatory monitoring was lower in the ranolazine arm, and treatment was generally well tolerated.

A large real-world cohort study in mixed HCM phenotypes reported substantial symptomatic improvement.16 Approximately three-quarters of patients experienced relief of angina, and around two-thirds improved by at least two Canadian Cardiovascular Society angina classes. These benefits were accompanied by reductions in self-reported exertional limitation, although formal exercise testing data were limited. Around one-fifth of patients discontinued treatment, mostly owing to non-serious adverse effects such as dizziness or gastrointestinal upset.

The smaller RHYME case series yielded concordant findings: in a cohort of symptomatic HCM patients treated with ranolazine, most experienced improvement in angina or dyspnoea, with acceptable tolerability over follow-up.24 Long-term registry data in refractory angina, although not specific to HCM, similarly suggest sustained symptomatic benefit and a favourable safety profile with ranolazine.25

Collectively, these studies indicate that ranolazine is best viewed as an adjunctive agent for symptom control and ventricular ectopy in HCM, rather than a therapy that improves global exercise capacity or diastolic indices.

SGLT2I Evidence in Hypertrophic Cardiomyopathy

Two studies evaluated SGLT2I therapy in patients with HCM and type 2 diabetes.17,18 However, the nature of SGLT2I exposure differed between them. In the prospective controlled cohort, exposure was primarily to empagliflozin and dapagliflozin in patients with non-obstructive HCM and concomitant diabetes, whereas the nationwide registry reflected broader real-world SGLT2I use in diabetic HCM. In the registry study, SGLT2I exposure included empagliflozin, dapagliflozin, canagliflozin, ipragliflozin and ertugliflozin, but outcomes were analysed collectively rather than by individual agent.17,18

In the prospective controlled cohort, the primary endpoint was a composite ‘responder’ outcome, defined as a reduction in E/e′ of ≥1.5 together with improvement of at least one NYHA class.17 At follow-up, 70.8% of patients in the SGLT2I group met the responder criteria, compared with 4.2% in the control group. Secondary outcomes were concordant: E/e′ and other diastolic indices improved, 6-minute walk distance increased by approximately 50 m, and natriuretic peptide levels fell in the treatment arm. Left ventricular mass indices were largely unchanged over the short follow-up, suggesting a predominantly functional, rather than structural, effect.

The nationwide registry analysis evaluated outcomes in HCM patients with diabetes receiving SGLT2I versus propensity-matched controls treated with other glucose-lowering therapies.18 SGLT2I use was associated with lower risks of the primary composite outcome of all-cause death and HHF (HR 0.76; 95% CI [0.67–0.86]), as well as all-cause mortality (HR 0.56; 95% CI [0.46–0.68]), HHF (HR 0.82; 95% CI [0.72–0.94]), sudden cardiac death (HR 0.50; 95% CI [0.33–0.77]) and ischaemic stroke (HR 0.74; 95% CI [0.62– 0.88]).18 Because these registry findings were based on pooled real-world SGLT2I exposure rather than agent-specific comparisons, they should be interpreted as class-level observational associations rather than proof of identical effects across all individual SGLT2I.

Taken together, the available data suggest that SGLT2I-based strategies are promising in diabetic HCM, particularly in non-obstructive or HFpEF-like phenotypes. However, the evidence remains study-specific and predominantly observational and is not sufficient to support a uniform class effect across all SGLT2I.

Synthesis of Findings across Drug Classes

A quantitative summary of agent-specific findings is presented in Table 3, including effects on exercise capacity, diastolic or mechanistic endpoints, symptoms, arrhythmia burden and overall interpretation.

Table 3: Summary of Agent-specific Clinical, Functional and Mechanistic Findings.

Agent/Class Study Design Population n Follow-up Main Endpoints
Trimetazidine Coats et al. 201915 RCT Symptomatic non-obstructive HCM 51 12 weeks Peak VO₂, 6-minute walk distance, E/e′, NT-proBNP, quality of life
Perhexiline Abozguia et al. 20104 Mechanistic RCT Symptomatic non-obstructive HCM 46 Mean 4.6 months Phosphocreatine-to-adenosine triphosphate ratio, normalised time to peak filling, peak VO₂, New York Heart Association class
Ranolazine Olivotto et al. 2018 (RESTYLE-HCM)14 RCT Symptomatic non-obstructive HCM 80 5 months Peak VO₂, E/e′, NT-proBNP, premature ventricular complex burden
Ranolazine Argirò et al. 202316 Retrospective cohort Mixed HCM 119 Median 2 years Angina, Canadian Cardiovascular Society class, arrhythmias, safety
Ranolazine Gentry et al. 2016 (RHYME)24 Case series Symptomatic HCM 11 8 weeks Angina, dyspnoea, quality of life
Sodium–glucose cotransporter 2 inhibitors Subramanian et al. 202317 Prospective controlled cohort Type 2 diabetes + non-obstructive HCM 48 6 months E/e′, New York Heart Association class, 6-minute walk distance, NT-proBNP
Sodium–glucose cotransporter 2 inhibitors Jung et al. 202518 Nationwide registry HCM + type 2 diabetes 4,126 Median 3 years Mortality, hospitalisation for heart failure, sudden cardiac death, stroke

HCM = hypertrophic cardiomyopathy; NT-proBNP = N-terminal pro b-type natriuretic peptide; RCT = randomised controlled trial.

Safety

Across the seven included studies, metabolic modulators and SGLT2I were generally well tolerated. Drug discontinuation rates ranged from 0 to approximately 20%, varying by agent and study design.

For trimetazidine, adverse events were infrequent and mostly mild, with no major safety concerns in the single RCT.15

Perhexiline required therapeutic drug monitoring to maintain plasma concentrations within the therapeutic range. When such monitoring was used, no severe hepatotoxicity, neuropathy or cardiac arrhythmias were reported over the trial period.4

Ranolazine was associated with occasional dizziness, gastrointestinal discomfort and, rarely, QT prolongation leading to discontinuation; however, no consistent pro-arrhythmic signal emerged, and ventricular ectopy generally improved rather than worsened.14,16,24 Long-term registry data in refractory angina also support a generally favourable safety profile.25

SGLT2I had a safety profile similar to that seen in broader diabetic and heart failure populations, with genitourinary infections and volume depletion events reported at low frequency.17–19,26,27 Only a small number of patients discontinued therapy for adverse effects in the HCM cohort study, and no new safety signals were observed in the national registry.17,18

Overall, within the limitations of relatively short follow-up and small trial sizes, none of the evaluated drug classes showed evidence of substantial harm in HCM when used in appropriate patients and with recommended monitoring.

Discussion

Principal Findings

This systematic review synthesises the available clinical and observational evidence for metabolic modulators and SGLT2I in hypertrophic cardiomyopathy. Three overarching themes emerge.

First, across all drug classes, the most consistent benefits relate to diastolic function, symptom burden and arrhythmia reduction, rather than large gains in peak exercise capacity. Perhexiline, a potent FAO inhibitor, produced concordant mechanistic and clinical improvements: myocardial PCr/ATP increased, exercise-induced diastolic impairment in nTTPF normalised and peak VO₂ and NYHA class improved in symptomatic non-obstructive HCM.4 In contrast, trimetazidine, a milder FAO inhibitor, did not improve peak VO₂, diastolic indices, natriuretic peptides or quality of life and was essentially neutral.15

Second, ranolazine consistently improved angina and reduced ventricular ectopy across one RCT, one large cohort and a case series, with additional long-term data from a refractory angina registry.14,16,24,25 However, it did not increase peak VO₂ or meaningfully change echocardiographic markers of diastolic function.14,16 Therefore, its clinical profile is best characterised as an anti-anginal and anti-ectopic adjunct, rather than a therapy that enhances global functional capacity.

Third, SGLT2I-based strategies showed a broad signal of potential benefit in diabetic HCM, including improved diastolic indices and functional status in a prospective cohort and favourable outcome associations in a nationwide registry.17,18 However, these data remain small scale or observational, diabetic-population specific and insufficient to establish uniform efficacy across all SGLT2I or HCM phenotypes.17,18

Altogether, current evidence supports a role for metabolic and SGLT2-targeted therapies as adjuncts that improve haemodynamics, filling pressures and symptoms in selected HCM phenotypes – particularly non-obstructive disease – while highlighting that exercise capacity is rarely transformed and no data exist in obstructive HOCM.4,14–18

Mechanistic Interpretation

The clinical patterns observed across drug classes are consistent with contemporary understanding of HCM as a disorder involving energetic inefficiency, microvascular dysfunction and abnormal calcium handling. These mechanisms provide a framework for interpreting why agents targeting substrate metabolism, InaL and haemodynamic–metabolic pathways may produce different clinical effects across HCM phenotypes. Energetic impairment can be assessed using ³¹P-MRS, while sarcomeric myosin dysregulation, impaired coronary flow reserve and fibrosis provide mechanistic links between altered energetics, microvascular dysfunction and adverse outcomes.28–31

The therapeutic rationale for metabolic modulation in HCM is based on several overlapping disease mechanisms, including impaired myocardial energetics, diastolic dysfunction, microvascular ischaemia and arrhythmogenic substrate. Figure 2 summarises the principal mechanistic targets and observed clinical findings for each therapeutic class or agent discussed in this review.

Figure 2: Mechanistic Framework for Metabolic and SGLT2-targeted Therapies in Hypertrophic Cardiomyopathy.

Figure 2:

Mechanistic and clinical effects are agent- and phenotype-specific and should not be interpreted as uniform class effects. 3-KAT = long-chain 3-ketoacyl-CoA thiolase; HCM = hypertrophic cardiomyopathy.

Against this mechanistic background, the divergent results of perhexiline and trimetazidine are instructive. Perhexiline inhibits carnitine palmitoyltransferase 1 and 2 and promotes a substrate shift away from FAO towards glucose oxidation, thereby improving ATP generation per unit of oxygen consumed.3,5 Therefore, the observed increase in PCr/ATP, correction of exercise-induced diastolic abnormalities and improvement in peak VO₂ are consistent with improved myocardial energetic efficiency in a myocardium under chronic energetic strain.4 In contrast, trimetazidine produces partial FAO inhibition through 3-KAT blockade and may have been insufficient to meaningfully alter myocardial substrate usage in symptomatic HCM.15 This distinction reinforces that metabolic modulators should not be interpreted as pharmacologically interchangeable, even when they target related energetic pathways.

Ranolazine operates through a different mechanistic axis. By inhibiting InaL, it reduces intracellular Na+ accumulation and secondary Ca²+ overload.13 Experimental work in human HCM myocytes suggests that InaL inhibition can shorten action-potential duration, reduce diastolic Ca²+ accumulation and suppress triggered activity.13 The clinical pattern observed in HCM, reduced ventricular ectopy and improvement in angina without consistent improvement in peak VO₂ or E/e′ is therefore biologically plausible.14,16,24,25 Ranolazine is best understood as an adjunct targeting microvascular angina and arrhythmic burden rather than as a global metabolic or disease-modifying therapy.

SGLT2I evidence should be interpreted separately from the FAO and InaL inhibitor data. These agents have plausible haemodynamic and metabolic mechanisms, including mild natriuresis, reduced filling pressures, improved ventricular–arterial coupling and possible effects on mitochondrial efficiency, inflammation and fibrosis.17–19 However, the HCM-specific evidence remains confined to diabetic populations and is not agent-specific. In the prospective cohort, empagliflozin/dapagliflozin exposure was associated with improved E/e′, NYHA class, 6-minute walk distance and NT-proBNP, while the nationwide registry reported favourable outcome associations across pooled real-world SGLT2I exposure.17,18 These findings are consistent with potential benefit in diabetic, non-obstructive or HFpEF-like HCM phenotypes, but they should not be interpreted as proof of a uniform therapeutic effect across all SGLT2I or all HCM phenotypes.

Together, these observations support a model in which metabolic and SGLT2-targeted therapies may improve selected downstream manifestations of HCM, particularly diastolic filling pressures, angina, functional status and ventricular ectopy, without directly correcting the underlying sarcomeric disease. Their clinical role is therefore likely to be adjunctive, phenotype-specific and dependent on careful selection of patients and endpoints.

Phenotype-specific Considerations

A striking feature of the available evidence is its near-total focus on non-obstructive or mixed HCM, with no trial designed specifically for obstructive HCM.4,14–18,24 Non-obstructive HCM is characterised by diastolic dysfunction, microvascular ischaemia and HFpEF-like haemodynamics, often in the absence of large LVOT gradients.2,5,6,26,32

By contrast, obstructive HCM is dominated by dynamic LVOT gradients, systolic anterior motion of the mitral valve and abnormal mitral–septal interaction.1,5,9,10 Therefore, extrapolating benefits from non-obstructive cohorts to obstructive HCM is uncertain, particularly for agents that alter preload or afterload. The relative contribution of energetic failure versus geometric obstruction may also differ between obstructive and non-obstructive phenotypes.2,3,11

Future trials in obstructive HCM should therefore incorporate rigorous haemodynamic characterisation, including resting and provoked LVOT gradients, exercise echocardiography, mitral valve and septal morphology, strain imaging and mechanistic endpoints such as PCr/ATP and perfusion reserve.1,3,5–7,30–32 Until such data are available, metabolic or SGLT2-targeted therapies in obstructive patients should be interpreted cautiously and used only within research settings or carefully monitored individualised care.1,4,14–18

Integration with Contemporary Hypertrophic Cardiomyopathy Therapy

The historical trajectory of HCM management has progressed from β-blockade and calcium channel blockade to disopyramide, septal reduction therapies and, most recently, cardiac myosin inhibition for obstructive disease.1,5,8–10 Whereas cardiac myosin inhibitors such as mavacamten and aficamten primarily address sarcomeric hypercontractility and LVOT obstruction in symptomatic obstructive HCM, the metabolic and SGLT2-targeted therapies reviewed here have been studied predominantly in non-obstructive or mixed HCM populations and therefore may be particularly relevant to phenotypes in which energetic inefficiency, diastolic dysfunction, microvascular ischaemia and ventricular ectopy are prominent drivers of symptoms.9,10

Within this framework, the agents examined in the present review are best positioned as adjunct therapies tailored to specific pathophysiological profiles:

  • Perhexiline provides the strongest human proof-of-concept that correcting energetic inefficiency can improve dynamic diastolic function and exercise capacity in non-obstructive HCM, but its narrow therapeutic window mandates specialised monitoring and limits widespread use.4,5

  • Ranolazine appears most appropriate for patients with microvascular angina and frequent ventricular ectopy, where it can meaningfully reduce chest pain and PVC burden, but should not be expected to enhance peak VO₂ or reverse diastolic dysfunction.14,16,24,25

  • Trimetazidine does not currently have a clear therapeutic niche in HCM based on neutral RCT data.15

  • SGLT2I-based strategies appear to be among the most promising adjunctive options, particularly in HCM with type 2 diabetes and HFpEF-like physiology, where they can improve diastolic indices, functional status and possibly prognosis, although the evidence base remains limited and study-specific rather than definitive for all individual agents.17–19,26,27

Importantly, none of these agents should displace guideline-directed therapies, including β-blockers, calcium channel blockers, myosin inhibitors in obstructive disease and appropriate arrhythmia prevention strategies. Rather, these agents should be viewed as complementary options in phenotypically selected patients, ideally within research or structured follow-up frameworks.1,5

Limitations

The available evidence has several limitations. Most interventional studies were small Phase II trials with sample sizes in the tens, limiting precision and the ability to detect infrequent adverse events. Follow-up was short (typically 4–6 months), preventing assessment of long-term outcomes such as disease progression, fibrosis or survival. Outcome definitions were heterogeneous – particularly for exercise capacity (variable cardiopulmonary protocols and 6-minute walk test) and diastolic function (E/e′, nTTPF and left atrial metrics) – precluding formal meta-analysis.

Phenotype reporting was often incomplete. Few studies clearly differentiated obstructive from non-obstructive HCM or quantified LVOT gradients. Advanced imaging endpoints such as perfusion MRI, strain, T1 mapping or serial fibrosis measurements were rarely included, and no study directly assessed effects on fibrosis progression or microvascular reserve.

Observational SGLT2I data are also vulnerable to confounding by indication and residual bias despite adjustment; patients receiving these agents may differ systematically from those who do not, making it difficult to isolate drug-specific effects from comorbidity management or glycaemic control.

This review has inherent limitations, including reliance on published data and the potential for publication bias. The need for narrative rather than quantitative synthesis – driven by small sample sizes and heterogeneity – limits direct comparison between agents, and risk-of-bias assessments cannot fully mitigate these structural weaknesses.

Future Directions

Future studies should be multicentre, phenotype-stratified and mechanistically integrated, incorporating advanced imaging and metabolic markers (PCr/ATP, perfusion reserve, strain and fibrosis) alongside standardised clinical endpoints.

With respect to SGLT2 inhibition, there is growing interest in sotagliflozin, a dual SGLT1/2 inhibitor with established efficacy in heart failure. Recent trials have demonstrated structural and functional benefits in HFpEF irrespective of diabetic status, supporting its potential relevance to HCM. In pre-clinical work using human living myocardial slice preparations, sotagliflozin improved diastolic mechanics and reduced tissue stiffness, providing mechanistic support for clinical evaluation.33

A post hoc analysis of the SCORED trial also reported that sotagliflozin significantly reduced cardiovascular events in patients with left ventricular hypertrophy without hypertension, a population that shares phenotypic overlap with non-obstructive HCM.34 These findings underpin the rationale for SONATA-HCM (NCT06481891), an ongoing Phase III randomised, double-blind, placebo-controlled study evaluating sotagliflozin in both obstructive and non-obstructive HCM. The trial will enrol approximately 500 patients worldwide and will assess changes in symptoms, functional capacity and patient-reported outcomes (Kansas City Cardiomyopathy Questionnaire Clinical Summary Score) over 26 weeks.

Another emerging metabolic therapy of interest in non-obstructive HCM is ninerafaxstat. Although it was not part of the original pre-specified intervention set and therefore was not included in the formal evidence base of this review, its recent Phase II placebo-controlled study provides contemporary support for metabolism-targeted therapy in this phenotype. In symptomatic non-obstructive HCM, ninerafaxstat was reported to be safe and well tolerated and was associated with significantly better ventilatory efficiency, with favourable health-status signals in more symptomatically limited patients.35

Combination strategies, such as pairing SGLT2I with myosin inhibition or targeted metabolic therapy in genotype-positive, phenotype-negative individuals, also warrant evaluation. Longer-term follow-up will be essential to determine whether metabolic and SGLT-targeted therapies can modify disease progression, myocardial energetics or fibrosis, rather than providing short-term symptomatic improvement alone.

Conclusion

Metabolic modulation is an emerging adjunctive strategy in HCM, with current evidence suggesting benefits mainly in diastolic function, symptoms and ventricular ectopy rather than consistent improvement in exercise capacity. Perhexiline provides the clearest proof-of-concept for improving myocardial energetics, whereas trimetazidine shows no meaningful clinical benefit. Ranolazine appears most useful for angina and ectopy rather than global functional improvement.

SGLT2I-based strategies show promising signals in diabetic, predominantly non-obstructive HCM, including improved diastolic parameters and favourable registry outcome associations. However, these findings remain study-specific and should not be interpreted as definitive class-wide efficacy.

Overall, metabolic and SGLT2-targeted therapies should be viewed as complementary to guideline-directed HCM management. Their future role will require rigorous, phenotype-stratified randomised studies assessing symptoms, exercise capacity, myocardial energetics, perfusion and long-term disease progression.

Acknowledgments

The authors acknowledge the use of ChatGPT 5.5 by OpenAI in the production of Figure 2.

References

  • 1.Ommen SR, Ho CY, Asif IM et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. Circulation. 2024;149:e1239–311. doi: 10.1161/CIR.0000000000001250. [DOI] [PubMed] [Google Scholar]
  • 2.Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–70. doi: 10.1161/CIRCRESAHA.117.311059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 2003;19:263–8. doi: 10.1016/S0168-9525(03)00081-7. [DOI] [PubMed] [Google Scholar]
  • 4.Abozguia K, Elliott P, McKenna W et al. Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation. 2010;122:1562–9. doi: 10.1161/CIRCULATIONAHA.109.934059. [DOI] [PubMed] [Google Scholar]
  • 5.Palandri C, Santini L, Argirò A et al. Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside. Drugs. 2022;82:889–912. doi: 10.1007/s40265-022-01728-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Pelliccia F, Cecchi F, Olivotto I, Camici PG. Microvascular dysfunction in hypertrophic cardiomyopathy. J Clin Med. 2022;11:6560. doi: 10.3390/jcm11216560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Valkovič L, Clarke WT, Schmid AI et al. Measuring inorganic phosphate and intracellular pH in the healthy and hypertrophic cardiomyopathy hearts by in vivo 7T 31P-cardiovascular magnetic resonance spectroscopy. J Cardiovasc Magn Reson. 2019;21:19. doi: 10.1186/s12968-019-0529-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847–51. doi: 10.1161/01.CIR.35.5.847. [DOI] [PubMed] [Google Scholar]
  • 9.Olivotto I, Oreziak A, Barriales-Villa R et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (Explorer-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396:759–69. doi: 10.1016/S0140-6736(20)31792-X. [DOI] [PubMed] [Google Scholar]
  • 10.Masri A, Sherrid MV, Abraham TP et al. Efficacy and safety of aficamten in symptomatic nonobstructive hypertrophic cardiomyopathy: results from the REDWOOD-HCM trial, Cohort 4. J Card Fail. 2024;30:1439–48. doi: 10.1016/j.cardfail.2024.02.020. [DOI] [PubMed] [Google Scholar]
  • 11.Ranjbarvaziri S, Kooiker KB, Ellenberger M et al. Altered cardiac energetics and mitochondrial dysfunction in hypertrophic cardiomyopathy. Circulation. 2021;144:1714–31. doi: 10.1161/CIRCULATIONAHA.121.053575. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Crilley JG, Boehm EA, Blair E et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41:1776–82. doi: 10.1016/S0735-1097(02)03009-7. [DOI] [PubMed] [Google Scholar]
  • 13.Coppini R, Ferrantini C, Yao L et al. Late sodium current inhibition reverses electromechanical dysfunction in human hypertrophic cardiomyopathy. Circulation. 2013;127:575–84. doi: 10.1161/CIRCULATIONAHA.112.134932. [DOI] [PubMed] [Google Scholar]
  • 14.Olivotto I, Camici PG, Merlini PA et al. Efficacy of ranolazine in patients with symptomatic hypertrophic cardiomyopathy: the RESTYLE-HCM randomized, double-blind, placebo-controlled study. Circ Heart Fail. 2018;11:e004124. doi: 10.1161/CIRCHEARTFAILURE.117.004124. [DOI] [PubMed] [Google Scholar]
  • 15.Coats CJ, Pavlou M, Watkinson OT et al. Effect of trimetazidine dihydrochloride therapy on exercise capacity in patients with nonobstructive hypertrophic cardiomyopathy: a randomized clinical trial. JAMA Cardiol. 2019;4:230–5. doi: 10.1001/jamacardio.2018.4847. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Argirò A, Zampieri M, Dei L-L et al. Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: real-world experience in a National Referral Center. Int J Cardiol. 2023;370:271–8. doi: 10.1016/j.ijcard.2022.10.014. [DOI] [PubMed] [Google Scholar]
  • 17.Subramanian M, Sravani V, Krishna SP et al. Efficacy of SGLT2 inhibitors in patients with diabetes and nonobstructive hypertrophic cardiomyopathy. Am J Cardiol. 2023;188:80–6. doi: 10.1016/j.amjcard.2022.10.054. [DOI] [PubMed] [Google Scholar]
  • 18.Jung MH, Cho JS, Lee SY et al. Sodium–glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study. Eur J Prev Cardiol. 2025;32:1103–11. doi: 10.1093/eurjpc/zwae345. [DOI] [PubMed] [Google Scholar]
  • 19.Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032–8. doi: 10.1136/heartjnl-2020-318060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Page MJ, McKenzie JE, Bossuyt PM et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi: 10.1136/bmj.n71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Sterne JAC, Savović J, Page MJ et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi: 10.1136/bmj.l4898. [DOI] [PubMed] [Google Scholar]
  • 22.Sterne JAC, Hernán MA, Reeves BC et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. doi: 10.1136/bmj.i4919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.National Heart, Lung, and Blood Institute. Study Quality Assessment Tools. 2021. [(accessed 20 November 2025)]. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools
  • 24.Gentry JL 3rd, Mentz RJ, Hurdle M, Wang A. Ranolazine for treatment of angina or dyspnea in hypertrophic cardiomyopathy patients (RHYME). J Am Coll Cardiol. 2016;68:1815–7. doi: 10.1016/j.jacc.2016.07.758. [DOI] [PubMed] [Google Scholar]
  • 25.Storey KM, Wang J, Garberich RF et al. Long-term (3 years) outcomes of ranolazine therapy for refractory angina pectoris (from the Ranolazine Refractory Registry). Am J Cardiol. 2020;129:1–4. doi: 10.1016/j.amjcard.2020.05.020. [DOI] [PubMed] [Google Scholar]
  • 26.Anker SD, Butler J, Filippatos G et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451–61. doi: 10.1056/NEJMoa2107038. [DOI] [PubMed] [Google Scholar]
  • 27.Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089–98. doi: 10.1056/NEJMoa2206286. [DOI] [PubMed] [Google Scholar]
  • 28.Tsampasian V, Cameron D, Sobhan R et al. Phosphorus magnetic resonance spectroscopy (31P MRS) and cardiovascular disease: the importance of energy. Medicina (Kaunas) 2023;59:174. doi: 10.3390/medicina59010174. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Toepfer CN, Garfinkel AC, Venturini G et al. Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy. Circulation. 2020;141:828–42. doi: 10.1161/CIRCULATIONAHA.119.042339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kofflard MJM, Michels M, Krams R et al. Coronary flow reserve in hypertrophic cardiomyopathy: relation with microvascular dysfunction and pathophysiological characteristics. Neth Heart J. 2007;15:209–15. doi: 10.1007/BF03085982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–7. doi: 10.1016/j.jcmg.2011.11.021. [DOI] [PubMed] [Google Scholar]
  • 32.Malik AA, Saraswati U, Miranda WR et al. Invasive cardiac hemodynamics in apical hypertrophic cardiomyopathy. J Am Heart Assoc. 2024;13:e032520. doi: 10.1161/JAHA.123.032520. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Taichman R, Lee B, Margulies K, Day SM. Translational Science 2024; Las Vegas, NV, US: Apr 3–5, 2024. Pre-clinical evaluation of SGLT1/2 inhibition with sotagliflozin in hypertrophic cardiomyopathy using living myocardial slices. Presented at: [Google Scholar]
  • 34.Davies MJ, Bhatt DL, Pitt B, Steg PG. Sotagliflozin reduces the risk of cardiovascular events in patients with left ventricular hypertrophy without hypertension: a post hoc analysis from SCORED. J Card Fail. 2024;30:262. doi: 10.1016/j.cardfail.2023.10.345. [DOI] [Google Scholar]
  • 35.Maron MS, Mahmod M, Abd Samat AH et al. Safety and efficacy of metabolic modulation with ninerafaxstat in patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2024;83:2037–48. doi: 10.1016/j.jacc.2024.03.387. [DOI] [PubMed] [Google Scholar]

Articles from European Cardiology Review are provided here courtesy of Radcliffe Cardiology

RESOURCES